Cuprina Holdings (Cayman) Ltd(CUPR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 5 at 4:00 PM ET (Korea 11/6 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.34 | Insider Own | 23.01% | Shs Outstand | 7.7M | Perf Week | -3.8% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 5.9M | Perf Month | -11.06% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 0.84% | Short Float | 0.24% | Perf Quarter | -46.69% |
| Income | -0.00B | P/S | 260.66 | EPS this Y | - | Inst Trans | 173.34% | Short Ratio | 0.13 | Perf Half Y | -16.19% |
| Sales | 0.00B | P/B | 1.21 | EPS next 5Y | - | ROA | -90.82% | Short Interest | 0.01M | Perf YTD | -44.7% |
| Book/sh | 1.47 | P/C | 4.31 | EPS past 3/5Y | -65.95% -75.01% | ROE | -1082.72% | 52W High | -88.04% ($14.80) | Perf Year | -74.86% |
| Cash/sh | 0.41 | P/FCF | - | Sales past 3/5Y | -2.38% -3.22% | ROIC | -85.52% | 52W Low | 22.49% ($1.45) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -208.64% | Gross Margin | -54.48% | Volatility(W/M) | 5.93% 9.14% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 209.66 | Sales Y/Y TTM | 6.3% | Oper. Margin | -9692.62% | ATR (14) | 0.19 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.35 | EPS Q/Q | -223.87% | Profit Margin | -9376.19% | RSI (14) | 41.49 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.35 | Sales Q/Q | 277.69% | SMA20 | -5.95% ($1.88) | Beta | 0.16 | Target Price | - |
| Payout | - | Debt/Eq | 0.1 | Earnings | - | SMA50 | -20.24% ($2.22) | Rel Volume | 0.45 | Prev Close | $1.92 |
| Employees | 10 | LT Debt/Eq | 0.07 | EPS/Sales Surpr. | - | SMA200 | -40.65% ($2.98) | Avg Volume(3M) | 0.11M | Price | $1.77 |
| IPO | 2025/4/10 | Option/Short | No/Yes | Trades | 280 | Volume | 51,787 | Change | -7.81% |
🩺 Biomedical device manufacturer specializing in chronic wound healing. Currently developing the MagicWim Therapy product. IPO in April 2025.
Over the past 1 year, on the lower side
88% below its 1-year high.
Traded less than usual. That is 45% of its average volume.
CUPR has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $26,066. Peers typically go for $246.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.8%.
Tap to view numbers
It ranks #49 of 51 in the industry
Based on market cap of $10M.
NXGL#47 Nexgel Inc $12M PER - 
FEMY#48 Femasys Inc $11M PER - CUPR#49 Cuprina Holdings (Cayman) Ltd $10M PER - 
RGNT#50 Regentis Biomaterials Ltd $8M PER - 
LUCY#51 Innovative Eyewear Inc $7M PER - 
FAQ
What kind of company is CUPR?
CUPR belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of CUPR?
The market cap of CUPR is approximately $10M, ranking 5,397 within its sector.
What is the 52-week high and low for CUPR?
CUPR has recorded a 52-week high of $14.80 and a low of $1.45.
